Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 25-02 / BIG 3-02 (TEXT) 

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

Tamoxifen and Exemestane Trial (TEXT)

DESIGN

please click on the picture to see a larger version

TEXT-Bone Substudy


The TEXT-Bone Substudy investigates serial bone markers for bone remodeling, serial growth factors, and bone mineral density for TEXT patients in selected centers.

Study Chairs
BIG: Dr. Olivia Pagani - Mendrisio, Switzerland
US Intergroup: Dr. Barbara Walley - Calgary, Canada


Statistician
Dr. Meredith Regan

Trial Coordinators
Karolyn Scott, Jocelyn Swick, Chris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg24-26_STP@fstrf.org


Date of Activation
August 4, 2003

Targeted Accrual
1845 patients

Other Pathology


News

27.08.2010:
Activation of IBCSG Trial 38-10/BIG 3-07/TROG 07.01

19.08.2010:
A few impressions from our audits

09.08.2010:
Latest SOLE flash

All News

 
  Print